shikshan nivesh/
    DataAI ConnectorGreekSoupServicesAbout
    Log inMake a free account
    shikshan nivesh/
    Make a free account
    SN DataUS
    AI ConnectorPricing
    DatasetsCompaniesScreenerEventsAPIAI Connector
    /
    Licence the data

    Data / Companies / BLLN

    BillionToOne, Inc.Nasdaq

    BLLN-US · CIK 0002070849 · Services-Medical Laboratories

    EDGAR

    $113.21

    Last close · 30 Oct 2026

    64.03 – 149.97

    52-week range

    $5.3B

    Market value

    $397.4M

    Revenue, LTM

    $37.7M

    Net income, LTM

    129.9×

    P/E, LTM

    27

    Filings held

    DES OverviewFA Financial statementsGP ChartsRAT RatiosERN ResultsSEG SegmentsEVT 8-K eventsFIL FilingsINS Insider tradesF144 Planned salesHDS Large holdersOWN Fund holdersPAY Executive payVOTE Shareholder votesCNG House tradesSI Short interestDVD DividendsPEER PeersABT About

    BLLN US Equity

    OverviewDESFinancial statementsFAChartsGPRatiosRATResultsERNSegmentsSEG8-K eventsEVTFilingsFILInsider tradesINSPlanned salesF144Large holdersHDSFund holdersOWNExecutive payPAYShareholder votesVOTEHouse tradesCNGShort interestSIDividendsDVDPeersPEERAboutABT

    Revenue by quarter

    US$ · last 8
    Hover a column for its exact figure
    $0$50M$100M$150M
    Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
    QuarterRevenueNet incomeEPS
    Q2 FY2026$109.4M$8.1M0.15
    Q1 FY2026$108.4M$18.0M0.34
    Q4 FY2025$96.1M$6.0M0.45
    Q3 FY2025$83.5M$5.7M0.10

    Newest filings

    All 27
    FormFiled
    10-Q5 Aug 2026
    8-K5 Aug 2026
    8-K29 Jun 2026
    8-K16 Jun 2026
    10-Q6 May 2026
    8-K6 May 2026
    ARS21 Apr 2026
    DEFA14A21 Apr 2026

    Description

    Ticker
    BLLN-US
    Exchange
    Nasdaq
    Index
    –
    Industry
    Services-Medical Laboratories
    SIC division
    Services
    CIK
    0002070849
    Fiscal year ends
    Dec
    Filings held
    27 since 2025
    8-K events
    8
    Shares short
    2.9M, 15 Oct 2026

    Financial statements

    The main lines of the income statement, balance sheet and cash flow, by year and by quarter. Each period opens its filing.

    3 years · US$ millions
    Fiscal periodFY2023FY2024FY2025
    Period ending31 Dec 202331 Dec 202431 Dec 2025
    Reported in10-K10-K10-K
    Report filed11 Mar 2026†11 Mar 2026†11 Mar 2026
    Revenue72M153M305M
    Cost of revenue54M72M97M
    Gross profit17M81M208M
    Gross margin24.1%53.0%68.3%
    Research and development22M37M49M
    Selling, general and administrative64M91M143M
    Operating income-69M-47M16M
    Operating margin-96.9%-30.9%5.3%
    Profit before tax-83M-42M8M
    Income tax0M0M0M
    Tax rate––3.9%
    Net income-83M-42M7M
    Net margin-115.3%-27.2%2.4%
    Earnings per share, diluted-8.45-4.120.14
    Diluted shares10M10M21M

    † Reported in a later filing that carries this period again, as a comparative or restated figure. The period's own original filing may show different numbers.

    Ratios

    Worked out the same way for every company. Hover a ratio for how it is calculated.

    Valuation
    Market cap
    $5.3B
    Price
    $113.21
    Stock P/E
    129.90×
    Price to book
    9.95×
    Enterprise value
    $4.9B
    EV / EBITDA
    97.24×
    Market cap / sales
    13.44×
    52-week high
    $149.97
    52-week low
    $64.03
    Profitability
    Gross margin, TTM
    71.3%
    Operating margin
    10.9%
    Net margin
    9.5%
    FCF margin
    8.3%
    ROE
    7.0%
    ROCE
    6.9%
    Cash conversion
    1.20×
    Interest cover
    1056.15×
    Effective tax rate, TTM
    0.5%
    Growth
    Balance sheet
    Cash and equivalents
    $548.6M
    Borrowings
    $91.0M
    Net debt
    -$457.6M
    Debt to equity
    0.17×
    Shareholders' equity
    $536.8M
    Total assets
    $729.7M
    Shareholders
    Shares outstanding
    47,187,038
    Share count, last 12 months
    346.8%

    What the company said with its results

    The key points, guidance and management's own words from each of the last four results releases.

    No results summary read for this company yet.

    Revenue by segment

    As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.

    By product, FY2025
    • Prenatal$277.1M 90.8%
    • Oncology$25.0M 8.2%
    • Clinical trial support and other services$3.1M 1.0%
    3 years held, FY2023 to FY2025

    Company events

    Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.

    5 Aug 20268-KResults2.02, 9.01
    29 Jun 20268-KMaterial agreementNew debt1.01, 2.03, 9.01
    16 Jun 20268-KMaterial agreementNew debt1.01, 2.03, 9.01
    6 May 20268-KResults2.02, 9.01
    4 Mar 20268-KResultsLeadership change2.02, 5.02, 9.01
    12 Jan 20268-KResultsInvestor update2.02, 7.01
    9 Dec 20258-KResultsLeadership change2.02, 5.02, 9.01
    10 Nov 20258-KBylaws or fiscal year changeOther events5.03, 8.01, 9.01
    8-K events each year
    Hover a column for its exact count
    0246
    '25'26

    Every filing

    The company's filings with the SEC, newest first: 27 held. Insider, fund and large-holder filings have their own tables below.

    5 Aug 202610-Q30 Jun 2026
    5 Aug 20268-K5 Aug 2026
    29 Jun 20268-K23 Jun 2026
    16 Jun 20268-K10 Jun 2026
    6 May 202610-Q31 Mar 2026
    6 May 20268-K6 May 2026
    21 Apr 2026ARS31 Dec 2025
    21 Apr 2026DEFA14A–
    21 Apr 2026DEF 14A10 Jun 2026
    11 Mar 202610-K31 Dec 2025
    4 Mar 20268-K4 Mar 2026
    12 Jan 20268-K12 Jan 2026
    10 Dec 202510-Q30 Sep 2025
    9 Dec 20258-K9 Dec 2025
    10 Nov 20258-K7 Nov 2025
    6 Nov 2025S-8–
    5 Nov 2025CERT–
    3 Nov 20258-A12B–
    17 Oct 2025S-1/A–
    7 Oct 2025S-1–
    17 Sep 2025DRSLTR–
    17 Sep 2025DRS/A–
    26 Aug 2025UPLOAD–
    11 Aug 2025DRSLTR–
    11 Aug 2025DRS/A–
    17 Jul 2025UPLOAD–
    20 Jun 2025DRS–

    Insider trades

    Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.

    28 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan8,333$118.00$983.3K030 Oct 2026
    28 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan2,667$118.00$314.7K146,50130 Oct 2026
    15 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan900$98.43$88.6K4,25016 Oct 2026
    15 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan1,861$99.84$185.8K2,38916 Oct 2026
    15 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan1,276$100.60$128.4K1,11316 Oct 2026
    15 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan980$101.79$99.8K13316 Oct 2026
    15 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan133$102.78$13.7K016 Oct 2026
    14 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan3,083$98.32$303.1K10016 Oct 2026
    14 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan100$99.00$9.9K016 Oct 2026
    14 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan2,667$98.00$261.4K149,16816 Oct 2026
    12 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan1,961$91.57$179.6K14,70614 Oct 2026
    12 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan2,553$93.05$237.5K12,15314 Oct 2026
    12 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan6,763$93.65$633.3K5,39014 Oct 2026
    12 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan3,869$94.61$366.1K1,52114 Oct 2026
    12 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan1,521$96.39$146.6K014 Oct 2026
    12 Oct 2026Atay OguzhanChairman and CEOSale under a trading plan2,667$97.61$260.3K151,83514 Oct 2026
    5 Oct 2026Ten Bosch John RoderickSVP of Laboratory OperationsSale under a trading plan1,417$105.15$149.0K19,3857 Oct 2026
    5 Oct 2026Tsao DavidChief Technology OfficerSale under a trading plan866$105.90$91.7K20,1347 Oct 2026
    5 Oct 2026Tsao DavidChief Technology OfficerSale under a trading plan1,909$107.19$204.6K18,2257 Oct 2026
    5 Oct 2026Tsao DavidChief Technology OfficerSale under a trading plan4,284$108.39$464.4K13,9417 Oct 2026
    5 Oct 2026Tsao DavidChief Technology OfficerSale under a trading plan2,921$109.00$318.4K11,0207 Oct 2026
    5 Oct 2026Tsao DavidChief Technology OfficerSale under a trading plan20$110.08$2.2K11,0007 Oct 2026
    5 Oct 2026Tsao DavidChief Technology OfficerSale under a trading plan555$105.56$58.6K10,4457 Oct 2026
    5 Oct 2026Tsao DavidChief Technology OfficerSale under a trading plan400$106.10$42.4K10,0457 Oct 2026
    5 Oct 2026Tsao DavidChief Technology OfficerSale under a trading plan2,200$107.47$236.4K7,8457 Oct 2026
    5 Oct 2026Tsao DavidChief Technology OfficerSale under a trading plan4,916$108.53$533.6K2,9297 Oct 2026
    5 Oct 2026Tsao DavidChief Technology OfficerSale under a trading plan1,829$109.14$199.6K1,1007 Oct 2026
    5 Oct 2026Tsao DavidChief Technology OfficerSale under a trading plan100$110.09$11.0K1,0007 Oct 2026
    28 Sep 2026Atay OguzhanChairman and CEOSale under a trading plan8,333$120.64$1.0M030 Sep 2026
    28 Sep 2026Atay OguzhanChairman and CEOSale under a trading plan2,666$120.64$321.6K154,50230 Sep 2026
    24 Sep 2026Tsao DavidChief Technology OfficerSale under a trading plan3,333$125.00$416.6K1,00028 Sep 2026
    24 Sep 2026Ten Bosch John RoderickSVP of Laboratory OperationsSale under a trading plan1,416$120.00$169.9K22,21928 Sep 2026
    21 Sep 2026Ten Bosch John RoderickSVP of Laboratory OperationsSale under a trading plan1,416$106.61$151.0K23,63523 Sep 2026
    17 Sep 2026Lynch Thomas P.See RemarksSale under a trading plan19,384$110.36$2.1M16,42821 Sep 2026
    17 Sep 2026Lynch Thomas P.See RemarksSale under a trading plan6,968$110.30$768.6K9,46021 Sep 2026
    17 Sep 2026Lynch Thomas P.See RemarksSale under a trading plan2,920$110.31$322.1K6,54021 Sep 2026
    17 Sep 2026Lynch Thomas P.See RemarksSale under a trading plan5,840$110.29$644.1K70021 Sep 2026
    14 Sep 2026Atay OguzhanChairman and CEOSale under a trading plan4,465$98.63$440.4K20,53416 Sep 2026
    14 Sep 2026Atay OguzhanChairman and CEOSale under a trading plan2,456$99.57$244.5K18,07816 Sep 2026
    14 Sep 2026Atay OguzhanChairman and CEOSale under a trading plan2,531$100.58$254.6K15,54716 Sep 2026
    14 Sep 2026Atay OguzhanChairman and CEOSale under a trading plan7,214$101.44$731.8K8,33316 Sep 2026
    14 Sep 2026Atay OguzhanChairman and CEOSale under a trading plan1,680$98.64$165.7K6,65316 Sep 2026
    14 Sep 2026Atay OguzhanChairman and CEOSale under a trading plan1,500$99.57$149.4K5,15316 Sep 2026
    14 Sep 2026Atay OguzhanChairman and CEOSale under a trading plan2,010$100.78$202.6K3,14316 Sep 2026
    14 Sep 2026Atay OguzhanChairman and CEOSale under a trading plan3,143$101.49$319.0K016 Sep 2026
    14 Sep 2026Atay OguzhanChairman and CEOSale under a trading plan2,666$98.00$261.3K157,16816 Sep 2026
    9 Sep 2026Ten Bosch John RoderickSVP of Laboratory OperationsSale under a trading plan1,416$97.54$138.1K25,05111 Sep 2026
    9 Sep 2026Tsao DavidChief Technology OfficerSale under a trading plan10,000$97.54$975.4K11,00011 Sep 2026
    9 Sep 2026Tsao DavidChief Technology OfficerSale under a trading plan10,000$100.00$1.0M1,00011 Sep 2026
    8 Sep 2026Lynch Thomas P.See RemarksSale under a trading plan38$96.47$3.7K20,66210 Sep 2026
    1–50 of 150

    Planned insider sales

    Form 144 notices, filed when the sell order goes to the broker.

    28 Oct 2026Atay OguzhanMember of immediate family of any of the foregoing2,667$314.7K28 Oct 2026
    28 Oct 2026Atay OguzhanOfficer, Director8,333$983.3K28 Oct 2026
    15 Oct 2026Atay OguzhanOfficer, Director5,150$516.2K15 Oct 2026
    14 Oct 2026Atay OguzhanMember of immediate family of any of the foregoing2,667$261.4K14 Oct 2026
    14 Oct 2026Atay OguzhanOfficer, Director3,183$313.0K14 Oct 2026
    13 Oct 2026Atay OguzhanMember of immediate family of any of the foregoing2,667$260.3K12 Oct 2026
    13 Oct 2026Atay OguzhanOfficer, Director16,667$1.6M12 Oct 2026
    5 Oct 2026Tsao DavidOfficer, Director1,750$184.0K5 Oct 2026
    5 Oct 2026ten Bosch John RoderickOfficer2,834$298.0K5 Oct 2026
    5 Oct 2026Tsao DavidOfficer, Director20,000$2.2M5 Oct 2026
    28 Sep 2026Atay OguzhanMember of immediate family of any of the foregoing2,666$321.6K28 Sep 2026
    28 Sep 2026Atay OguzhanOfficer, Director8,333$1.0M28 Sep 2026
    24 Sep 2026ten Bosch John RoderickOfficer1,416$169.9K24 Sep 2026
    24 Sep 2026Tsao DavidOfficer, Director3,333$416.6K24 Sep 2026
    21 Sep 2026ten Bosch John RoderickOfficer1,416$151.0K21 Sep 2026
    17 Sep 2026Lynch Thomas P.Officer35,112$3.9M17 Sep 2026
    14 Sep 2026Atay OguzhanMember of immediate family of any of the foregoing5,332$522.5K14 Sep 2026
    14 Sep 2026Atay OguzhanOfficer, Director24,999$2.5M14 Sep 2026
    9 Sep 2026ten Bosch John RoderickOfficer1,416$138.1K9 Sep 2026
    9 Sep 2026Tsao DavidOfficer, Director1,750$170.7K9 Sep 2026
    9 Sep 2026Tsao DavidOfficer, Director20,000$2.0M9 Sep 2026
    8 Sep 2026Lynch Thomas P.Officer20,000$2.0M8 Sep 2026
    25 Aug 2026ten Bosch John RoderickOfficer1,417$141.7K25 Aug 2026
    25 Aug 2026Tsao DavidOfficer, Director10,000$1.0M25 Aug 2026
    10 Aug 2026ten Bosch John RoderickOfficer1,417$131.6K10 Aug 2026
    10 Aug 2026Tsao DavidOfficer, Director3,500$325.0K10 Aug 2026
    10 Aug 2026Tsao DavidOfficer, Director10,000$928.6K10 Aug 2026
    5 Aug 2026Atay OguzhanOfficer, Director15,539$2.3M5 Aug 2026
    3 Aug 2026Atay OguzhanOfficer, Director2,500$343.4K3 Aug 2026
    3 Aug 2026Atay OguzhanMember of immediate family of any of the foregoing12,500$1.7M3 Aug 2026
    3 Aug 2026Atay OguzhanOfficer, Director32,500$4.5M3 Aug 2026
    31 Jul 2026Sakakibara Shan RikuOfficer4,000$560.8K31 Jul 2026
    16 Jul 2026Johnson Nancy JoAnnOfficer14,199$1.8M16 Jul 2026
    13 Jul 2026Tsao DavidOfficer, Director20,000$250.5K13 Jul 2026
    13 Jul 2026Tsao DavidOfficer, Director3,500$439.1K13 Jul 2026
    13 Jul 2026ten Bosch John RoderickOfficer4,251$533.3K13 Jul 2026
    9 Jul 2026Sakakibara Shan RikuOfficer8,000$1.0M9 Jul 2026
    9 Jul 2026Atay OguzhanOfficer, Director12,500$1.6M9 Jul 2026
    6 Jul 2026Atay OguzhanOfficer, Director2,500$300.0K6 Jul 2026
    6 Jul 2026Atay OguzhanMember of immediate family of any of the foregoing12,500$1.5M6 Jul 2026
    6 Jul 2026Atay OguzhanOfficer, Director26,250$3.1M6 Jul 2026
    1 Jul 2026Johnson Nancy JoAnnOfficer801$100.1K1 Jul 2026
    29 Jun 2026ten Bosch John RoderickOfficer1,416$169.9K29 Jun 2026
    24 Jun 2026Sakakibara Shan RikuOfficer8,000$880.0K24 Jun 2026
    15 Jun 2026ten Bosch John RoderickOfficer2,832$287.4K15 Jun 2026
    15 Jun 2026Tsao DavidOfficer, Director3,500$355.1K15 Jun 2026
    15 Jun 2026Tsao DavidOfficer, Director20,000$2.0M15 Jun 2026
    9 Jun 2026Johnson Nancy JoAnnOfficer10,582$1.1M9 Jun 2026
    8 Jun 2026Atay OguzhanOfficer, Director2,500$245.6K8 Jun 2026
    8 Jun 2026Johnson Nancy JoAnnOfficer3,418$339.3K8 Jun 2026
    1–50 of 53

    Large holders

    Schedule 13D and 13G filings by holders of more than 5% of the voting shares.

    17 Feb 2026David Tsao13G6.9%3.0M
    17 Feb 2026Oguzhan Atay13G7.3%3.2M
    13 Feb 2026NeoTribe Ventures I, L.P. ("NTV I")13G10.6%4.4M
    20 Jan 2026Hummingbird Ventures Management NV13D19.6%7.9M

    Trades by members of the House

    From each member's periodic transaction report: the amount is the band the report gives.

    No House trades in this company.

    Short interest

    Shares sold short and not yet bought back, on every FINRA settlement date.

    Shares short, each settlement
    15 Oct 20262.9M+4.04%5.53
    30 Sep 20262.8M+7.34%3.88
    15 Sep 20262.6M+11.79%4.84
    31 Aug 20262.3M+20.49%4.17
    14 Aug 20261.9M+1.49%1.8
    31 Jul 20261.9M-20.21%3.38
    15 Jul 20262.4M-0.71%3.58
    30 Jun 20262.4M+34.2%2.96
    15 Jun 20261.8M+7.41%2.18
    29 May 20261.7M+14.77%2.82
    1–10 of 23

    Funds that hold it

    Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.

    Funds holding

    166

    quarter to 30 Jun 2026

    Added or new

    125

    since 31 Mar 2026

    Trimmed

    13

    in the quarter

    Largest holder

    Adams Street Partners LLC

    $205.3M

    The 60 largest of 166 funds, by value
    Adams Street Partners LLC$205.3M1.7M0Held46.39%Filing ↗
    Price T Rowe Associates Inc.$121.2M1.0M+272.8KAdded0.01%Filing ↗
    Baillie Gifford & Co.$108.2M901.4K-358.6KTrimmed0.10%Filing ↗
    Vanguard Portfolio Management LLC$100.9M841.0K+689.8KAdded0.01%Filing ↗
    Invesco Ltd.$100.3M835.6K+429.1KAdded0.01%Filing ↗
    Vanguard Capital Management LLC$95.9M799.5K+617.0KAdded0.00%Filing ↗
    Neuberger Berman Group LLC$91.7M764.2K+55.0KAdded0.06%Filing ↗
    Bamco Inc.$89.0M742.1K+608Held0.13%Filing ↗
    Wasatch Advisors LP$62.2M518.1K+148.4KAdded0.41%Filing ↗
    Millennium Management LLC$51.0M425.0K+425.0KNew0.04%Filing ↗
    Fuller & Thaler Asset Management, Inc.$50.2M418.6K+418.6KNew0.14%Filing ↗
    Emerald Advisers, LLC$45.1M375.9K+136.3KAdded1.06%Filing ↗
    Next Century Growth Investors LLC$43.7M364.5K+273.9KAdded2.32%Filing ↗
    UBS Group AG$41.3M344.3K+222.7KAdded0.01%Filing ↗
    JPMorgan Chase & Co.$41.0M340.4K+57.2KAdded0.00%Filing ↗
    Ameriprise Financial Inc.$38.5M320.6K+100.6KAdded0.01%Filing ↗
    Oberweis Asset Management Inc.$35.9M299.0K+299.0KNew0.74%Filing ↗
    Wells Fargo & Company$32.6M271.6K+270.4KAdded0.01%Filing ↗
    Napean Trading & Investment Co (Singapore) PTE Ltd$28.0M233.3K0Held9.62%Filing ↗
    UBS AM, a distinct business unit of UBS Asset Management Americas LLC$26.9M223.9K-16.7KTrimmed0.01%Filing ↗
    Emerald Mutual Fund Advisers Trust$24.5M204.0K+71.8KAdded0.86%Filing ↗
    AllianceBernstein L.P.$20.7M262.1K+38.9KAdded0.01%Filing ↗
    Penn Capital Management Company, LLC$15.5M129.6K+3.3KAdded0.99%Filing ↗
    BNP Paribas Financial Markets$14.7M122.5K+122.5KAdded0.01%Filing ↗
    Goldman Sachs Group Inc.$14.4M120.3K+116.2KAdded0.00%Filing ↗
    New York State Common Retirement Fund$14.1M117.8K+29.1KAdded0.02%Filing ↗
    Voloridge Investment Management, LLC$14.0M117.1K+117.1KNew0.06%Filing ↗
    BlackRock, Inc.$13.7M114.3K+19.1KAdded0.00%Filing ↗
    Fred Alger Management, LLC$13.7M114.1K+114.1KNew0.05%Filing ↗
    Renaissance Technologies LLC$11.6M96.6K+45.3KAdded0.02%Filing ↗
    T. Rowe Price Investment Management, Inc.$11.2M93.0K+93.0KNew0.01%Filing ↗
    Geode Capital Management, LLC$10.6M87.9K-1.2KTrimmed0.00%Filing ↗
    Perceptive Advisors LLC$10.4M86.8K-5.0KTrimmed0.16%Filing ↗
    Lord, Abbett & Co. LLC$10.4M86.3K+42.0KAdded0.03%Filing ↗
    Healthcare of Ontario Pension Plan Trust Fund$10.0M83.3K+83.3KNew0.01%Filing ↗
    HRT Financial LP$9.7M80.7K+80.7KNew0.02%Filing ↗
    Massachusetts Financial Services Co.$9.5M79.0K-80.6KTrimmed0.00%Filing ↗
    Greenwich Wealth Management LLC$8.6M71.6K+71.6KNew0.31%Filing ↗
    Blue Water Life Science Advisors, LP$8.4M70.0K+50.0KAdded5.29%Filing ↗
    TD Asset Management Inc$7.6M63.5K+20.4KAdded0.01%Filing ↗
    Bank of America Corp.$7.1M59.0K+46.3KAdded0.00%Filing ↗
    Verition Fund Management LLC$6.8M57.0K+57.0KNew0.05%Filing ↗
    Susquehanna International Group, LLP$6.6M54.6K+42.1KAdded0.01%Filing ↗
    Ensign Peak Advisors, Inc$6.2M51.4K-74Trimmed0.01%Filing ↗
    Jump Financial, LLC$5.6M46.3K+46.3KNew0.05%Filing ↗
    Marshall Wace, LLP$5.4M44.7K+44.7KNew0.01%Filing ↗
    Fox Hill Wealth Management$5.2M43.7K+43.7KNew2.10%Filing ↗
    F/m Investments LLC$5.2M43.6K+26.7KAdded0.27%Filing ↗
    Weiss Asset Management LP$5.2M43.1K+43.1KNew0.07%Filing ↗
    Vanguard Fiduciary Trust Co.$5.1M42.9K+15.1KAdded0.00%Filing ↗
    1–50 of 60

    Dividends and buybacks

    Dividend per share, the cash paid and the shares bought back, each fiscal year.

    This company has paid no dividend in the years held.

    Peers

    Companies in the same industry, largest first, on the same measures.

    CompanyMarket valueRevenue, 12 monthsRevenue growthOperating marginNet marginROEP/EEV/EBITDA
    BillionToOne, Inc.this company$5.3B$397.4M–10.9%9.5%7.0%129.9×97.2×
    Natera, Inc.$59.5B$2.7B37.8%-10.7%-7.1%-10.6%––
    Labcorp Holdings Inc.$29.4B$14.6B6.0%10.3%6.9%11.3%29.7×15.8×
    Quest Diagnostics Inc.$27.7B$11.8B9.1%14.6%9.5%14.8%25.1×14.1×
    Guardant Health, Inc.$23.9B$1.2B42.7%-39.7%-38.3%–––
    Caris Life Sciences, Inc.$9.7B$989.6M–15.5%10.6%17.8%95.3×54.0×
    Grail, Inc.$6.4B$165.3M23.1%-338.4%-236.9%-15.4%––
    RadNet, Inc.$5.8B$2.3B18.9%3.1%-0.9%-1.9%–26.4×
    CareDx, Inc.$4.6B$497.4M38.9%23.4%25.9%27.5%36.6×32.3×
    Veracyte, Inc.$4.0B$561.9M17.3%18.8%20.4%8.2%35.5×29.4×
    Fortrea Holdings Inc.$2.1B$2.7B-3.4%0.5%-2.6%-12.9%–31.6×

    What the company does

    The description for this company is being written.

    Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence

    Data

    • United States
    • Datasets
    • Companies
    • Company events
    • Filings explained

    Reference

    • API
    • For AI assistants
    • Schemas
    • Coverage
    • Changelog
    • Status

    Licence and legal

    • Data licence
    • Terms
    • Privacy
    • Disclaimer
    • Refunds

    Shikshan Nivesh

    • About
    • GreekSoup
    • Newsletter
    • Alpha with AI Club
    • Services
    • For teams
    • Contact
    SN Data by Shikshan Nivesh · © 2026 Borkar Nexus Private LimitedNot investment advice. info@shikshannivesh.com